# Jonathan Synett

> Jonathan Synett is a seed investor at NCL Technology Ventures backing Health Care. See 7 investments, check sizes, portfolio and contact details. Updated Aug…

- Type: Angel Investor
- Fund: [NCL Technology Ventures](https://shizune.co/investors/profile/ncl)
- Location: London, United Kingdom
- Total investments: 7
- Last investment: Jun 2020
- Lead investor: 43%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jonathansynett

Jonathan Synett is a seed investor at NCL Technology Ventures in London focused on Health Care and Medical. Jonathan Synett - Chief Investment Officer @ NCL Technology Ventures

## Contacts

5 contacts available for Jonathan Synett: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/jonathan-synett?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 86% |
| Medical | 3 | 43% |
| Therapeutics | 3 | 43% |
| Biotechnology | 3 | 43% |
| Medical Device | 2 | 29% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 5 | 71% |
| Series A | 2 | 29% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 4 | 57% |
| Israel | 1 | 14% |
| Ireland | 1 | 14% |
| United States | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CuResponse | Curesponse is a medical company developing a three-dimensional tissue culture system for modeling cancer growth and drug response. The company's technology represents the next step in personalized cancer medicine, moving prediction capabilities beyond genomics and into the world of functional response on living patient cells. The platformpreserves the cancer tissue architecture, including the vasculature and immune system, accurately reflecting the cancer growth found in the body.Curesponse’s cutting edge functional platform will match the correct drug to the patient's cancer, improving survival and saving unnecessary medical interventions. The company is harnessing the technology to create a personalized cancer diagnostic assay that can be used to determine the drug response for a specific individual's tumor type. | $6M | Series A | Jun 05, 2020 | https://www.curesponse.com |
| Azadyne | Azadyne’s novel approach to treating autoimmune disease focuses on an unexplored pathway in the body and is based on research conducted at Trinity by Associate Professor in Biochemistry Vincent Kelly, Professor of Synthetic Chemistry Professor Stephen Connon and assistant Professor in Chemistry John Michael Southern. | $2M | Seed | Mar 27, 2019 | http://azadyne.com/ |
| Sana Health | Sana Health is an audio-visual neuromodulation device, that provides anxiety relief on-demand - multiple applications in pain and mental health, 2 pivotal studies are underway in Fibromyalgia (FDA designated breakthrough device) and Neuropathic Pain. Anxiety and PTSD trials starting in Q2 2022, DoD grant for PTSD.SOSV, Founders Fund, Noetic Fund,Harmonix, Dreamit, Esplanade, Bridge Builders Collective, Menlo Ventures. | $4.3M | Seed | Jul 17, 2018 | http://www.sana.io |
| Andiamo | Custom medical wearables platform |  | Seed | Mar 01, 2018 |  |
| Peptinnovate | Peptinnovate Limited, is a U.K. drug development company developing a ‘first in class’ immune regulating therapy for inflammatory diseases. | $3.4M | Series A | Jun 17, 2017 | https://peptinnovate.com/ |
| TC BioPharm | TC BioPharm develops safer, cheaper, consistent, and durable CAR-T drugs for hematological and solid tumors. TC BioPharm’s mission is to develop and commercialize innovative cell-based products to treat disease, improving patient health and quality of life.TC BioPharm is a clinical development company with a cell-based product pipeline capable oftreating a variety of disorders, including cancer and severe viral infections. TCB is currently conducting Phase II/III clinical studies of its lead product, ImmuniCell, in renal cell cancinoma, non-small cell lung cancer and melanoma patients. | $1.5M | Seed | May 01, 2016 | http://www.tcbiopharm.com/ |
| Centauri Therapeutics | Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases. The Alphamer technology is based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight theinfection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection. Centauri Therapeutics’ strategy is to redirect naturally occurring antibodies to target disease. Centauri Therapeutics' unique Chemistry Platform provides a flexible scaffold to enable the synthesis of specific Alphamers. These are bifunctional molecules which present a selective cell binding moiety as well as an epitope that recruits pre-existing antibodies, resulting in cell killing. Centauri Therapeutics believes their technology is widely applicable in the treatment of life threatening infectious diseases. Companies with an interest in accessing Centauri’s Alphamer technology or with an interest in one of their current projects, are warmly encouraged to contact them to discuss partnering opportunities. In order to drive success in the important area of immuno-oncology, Centauri Therapeutics has established a joint venture, Avvinity Therapeutics, with Horizon Discovery in March 2016. Avvinity combines Centauri’s Alphamer Technology with the gene editing and oncology expertise of Horizon. In addition to Centauri Therapeutics' immuno-oncology joint venture, Centauri maintains a strong network of collaborators in the areas of aptamer selection, drug discovery, chemistry and immunology. | $3.8M | Seed | Jan 19, 2016 | http://www.centauritherapeutics.com |

7 of 7 investments shown.

## Co-investors
- [Alfabeat](https://shizune.co/investors/profile/alfabeat) — VC Fund, 1 deal together
- [aMoon Fund](https://shizune.co/investors/profile/amoon) — VC Fund, 1 deal together
- [Bethnal Green Ventures](https://shizune.co/investors/profile/bethnal-green-ventures) — VC Fund, 1 deal together
- [DigitalHealth.London Accelerator](https://shizune.co/investors/profile/digitalhealth-london-accelerator) — VC Fund, 1 deal together
- [HealthTech Capital](https://shizune.co/investors/profile/healthtech-capital) — VC Fund, 1 deal together
- [Storm Global](https://shizune.co/investors/profile/schindleram-ventures) — VC Fund, 1 deal together

## About NCL Technology Ventures

VC Fund · London, United Kingdom

NCL is a specialist investment manager and advisory boutique that acts as a commercialisation engine for disruptive technology SMEs. NCL started in 2010 as Narec Capital, a joint venture with the UK’s National Renewable Energy Centre. Its primary purpose was to commercialise the IP that came through the centre of excellence, on behalf of UK Plc.NCL exploits the commercialisation stage funding gap by identifying truly high potential technologies and providing them with both the resource and institutional investment capital required to turn them into high performing SMEs. They are true venture managers with an inherent technology backbone.Guided by a highly experienced investment committee and leading scientific advisory board, NCL have deployed over $55M into the health sector, as a lead investor, over the last 3 years.

3 contacts available at NCL Technology Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Graham Hutchins | Chief Operating Officer | https://shizune.co/investors/profile/graham-hutchins |
| Jermey Biggs | Founder & CEO | https://shizune.co/investors/profile/jerry-biggs |
| Jonathan Synett | Chief Investment Officer | https://shizune.co/investors/profile/jonathan-synett |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Jonathan Synett invest in?

Jonathan Synett invests primarily in Health Care, Medical and Therapeutics startups, most often at Seed and Series A stage. Most of the 7 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Jonathan Synett?

Public channels for Jonathan Synett include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Jonathan Synett last invest?

The most recent investment recorded for Jonathan Synett closed in Jun 2020. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co